Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Update

Harvard Bioscience, Inc. (NASDAQ:HBIO) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 398,900 shares, a growth of 13.8% from the October 15th total of 350,600 shares. Based on an average daily volume of 116,700 shares, the short-interest ratio is presently 3.4 days.

Harvard Bioscience Price Performance

Shares of HBIO traded up $0.10 during trading hours on Monday, reaching $2.24. 31,639 shares of the company traded hands, compared to its average volume of 116,807. The company has a quick ratio of 0.94, a current ratio of 2.06 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $97.70 million, a PE ratio of -6.67 and a beta of 1.31. The stock has a fifty day simple moving average of $2.52 and a 200 day simple moving average of $2.89. Harvard Bioscience has a fifty-two week low of $2.12 and a fifty-two week high of $5.56.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in Harvard Bioscience by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock valued at $2,455,000 after buying an additional 19,972 shares during the last quarter. Barclays PLC lifted its holdings in Harvard Bioscience by 304.4% in the third quarter. Barclays PLC now owns 58,655 shares of the medical instruments supplier’s stock worth $157,000 after purchasing an additional 44,150 shares during the period. State Street Corp lifted its holdings in shares of Harvard Bioscience by 1.1% in the third quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock valued at $1,930,000 after buying an additional 7,763 shares during the period. Harvey Partners LLC boosted its stake in shares of Harvard Bioscience by 6.2% during the 3rd quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock worth $7,303,000 after acquiring an additional 157,500 shares in the last quarter. Finally, Corsair Capital Management L.P. acquired a new position in Harvard Bioscience in the 3rd quarter worth approximately $63,000. 80.87% of the stock is owned by hedge funds and other institutional investors.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.